Provided by Tiger Fintech (Singapore) Pte. Ltd.

Connect Biopharma Holdings Ltd.

0.7392
-0.0908-10.94%
Post-market: 0.77000.0308+4.17%19:50 EDT
Volume:103.78K
Turnover:83.01K
Market Cap:40.91M
PE:-2.61
High:0.8800
Open:0.8500
Low:0.7334
Close:0.8300
Loading ...

Company Profile

Company Name:
Connect Biopharma Holdings Ltd.
Exchange:
NASDAQ
Establishment Date:
2012
Employees:
62
Office Location:
3580 CARMEL MOUNTAIN ROAD,SUITE 200,San Diego,California,United States
Zip Code:
92130
Fax:
858 614 7007
Introduction:
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on developing therapies to treat T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is CBP-201, an antibody to target interleukin-4 receptor alpha in development for the treatment of atopic dermatitis (AD) and asthma. The company's product candidates also comprise CBP-307, a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis; and CBP-174, a peripherally acting antagonist of histamine receptor 3 in development for the treatment of pruritus associated with skin inflammation. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.

Directors

Name
Position
Barry Quart
Chief Executive Officer and Director
Kleanthis G. Xanthopoulos
Chairman of the Board
James Zuie chin Huang
Director
Jean Liu
Director
Kan Chen
Director
Karen J. Wilson
Director

Shareholders

Name
Position
Barry Quart
Chief Executive Officer and Director
David Szekeres
President
Jeff Cohn
General Counsel and Corporate Secretary
Kimberly J. Manhard
Executive Vice President, Chief Development Officer
Lei Sun
Vice President, Biologics and Head of CMC
Lisa Peraza
Vice President, Finance
Raúl Collazo
Vice President, Global Medical Affairs